Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT])

被引:94
作者
Felmeden, DC [1 ]
Spencer, CGC [1 ]
Chung, NAY [1 ]
Belgore, FM [1 ]
Blann, AD [1 ]
Beevers, DG [1 ]
Lip, GYH [1 ]
机构
[1] Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
关键词
D O I
10.1016/S0002-9149(03)00657-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increasing evidence points toward a prothrombotic state in hypertension and atherosclerosis, conditions associated with thrombosis-related complications, such as myocardial infarction and stroke. We hypothesized that this increased risk of thrombogenesis may be related to endothelial damage/dysfunction and abnormal angiogenesis, and thus, an increased risk of future cardiovascular disease. Thrombogenesis, endothelial damage/dysfunction, and angiogenesis can be assessed by measurement of tissue factor (TF), von Willebrand Factor (vWF), flow-mediated dilatation (FMD), and vascular endothelial growth factor (VEGF), respectively. To test this hypothesis, we measured TF, vWF, FMD, and VEGF in 76 patients with systemic hypertension (71 men; mean age 64; mean blood pressure 167/72 mm Hg), considered additional risk factors such as diabetes, and related them to the patient's 10-year cardiovascular and cerebrovascular risk score using the Framingham equation. Patients were compared with 48 healthy normotensive controls. In these patients, the effects of 6 months of intensified blood pressure and (where appropriate) lipid-lowering treatment were investigated. In our patients, TF, VEGF, and vWF levels were higher, but FMD was lower (all p <0.001) compared with the controls. All markers correlated with each other and with both cardiovascular and cerebrovascular risk scores (all p <0.001). After intensified blood pressure and hypercholesterolemia treatment, total cholesterol, blood pressure, TF, VEGF, and vWF levels all decreased, whereas FMD increased (all p <0.001). Thus, in subjects with hypertension and other risk factors, endothelial damage/dysfunction (and thus, atherogenesis), thrombogenesis, and angiogenesis are abnormal, correlate with overall cardiovascular risk, and importantly, can be related to each other in a "Birmingham Vascular Triangle." Furthermore, these processes are beneficially affected by intensive blood pressure and lipid treatment. ©2003 by Excerpta Medica, Inc.
引用
收藏
页码:400 / 405
页数:6
相关论文
共 30 条
[1]   CLOSE RELATION OF ENDOTHELIAL FUNCTION IN THE HUMAN CORONARY AND PERIPHERAL CIRCULATIONS [J].
ANDERSON, TJ ;
UEHATA, A ;
GERHARD, MD ;
MEREDITH, IT ;
KNAB, S ;
DELAGRANGE, D ;
LIEBERMAN, EH ;
GANZ, P ;
CREAGER, MA ;
YEUNG, AC ;
SELWYN, AP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (05) :1235-1241
[2]   Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension [J].
Belgore, FM ;
Blann, AD ;
Li-Saw-Hee, FL ;
Beevers, DG ;
Lip, GYH .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (06) :805-+
[3]   Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-I, in fluid samples: development and application of two new immunoassays [J].
Belgore, FM ;
Blann, AD ;
Lip, GY .
CLINICAL SCIENCE, 2001, 100 (05) :567-575
[4]   Von Willebrand factor and soluble E-selectin in hypertension: Influence of treatment and value in predicting the progression of atherosclerosis [J].
Blann, AD ;
Waite, MA .
CORONARY ARTERY DISEASE, 1996, 7 (02) :143-147
[5]   Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls [J].
Blann, AD ;
Amiral, J ;
McCollum, CN ;
Lip, GYH .
ATHEROSCLEROSIS, 2000, 152 (01) :29-34
[6]   The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications [J].
Blann, AD ;
Yip, GYH .
BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (04) :297-306
[7]   Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of Fluvastatin or Fenofibrate [J].
Blann, AD ;
Belgore, FM ;
Constans, J ;
Conri, C ;
Lip, GYP .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (10) :1160-1163
[8]   Vascular endothelial growth factor and its receptor, Flt-l, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes [J].
Blann, AD ;
Belgore, FM ;
McCollum, CN ;
Silverman, S ;
Lip, PL ;
Lip, GYH .
CLINICAL SCIENCE, 2002, 102 (02) :187-194
[9]  
BLANN AD, 1993, J HUM HYPERTENS, V7, P107
[10]  
Clarkson P, 1997, CIRCULATION, V96, P3378